Repeated naloxone administration in schizophrenia: A phase II world health organization study

D. Pickar, W. E. Bunney, P. Douillet, B. B. Sethi, M. Sharma, M. E. Vartanian, R. P. Lideman, D. Naber, K. Leibl, I. Yamashita, T. Koyama, W. M A Verhoeven, F. Vartanian, P. V. Morozov, T. Ngo Khac

Research output: Contribution to journalArticle

Abstract

In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptictreated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.

Original languageEnglish (US)
Pages (from-to)440-448
Number of pages9
JournalBiological Psychiatry
Volume25
Issue number4
DOIs
StatePublished - Feb 15 1989
Externally publishedYes

ASJC Scopus subject areas

  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Repeated naloxone administration in schizophrenia: A phase II world health organization study'. Together they form a unique fingerprint.

  • Cite this

    Pickar, D., Bunney, W. E., Douillet, P., Sethi, B. B., Sharma, M., Vartanian, M. E., Lideman, R. P., Naber, D., Leibl, K., Yamashita, I., Koyama, T., Verhoeven, W. M. A., Vartanian, F., Morozov, P. V., & Khac, T. N. (1989). Repeated naloxone administration in schizophrenia: A phase II world health organization study. Biological Psychiatry, 25(4), 440-448. https://doi.org/10.1016/0006-3223(89)90197-2